Logo
x

Search category

Subscribe Now

Phase 3 Trials

Regeneron's Dupixent (Dupilumab) Achieves 1EP & 2EP in two P-III trial for Inadequately-Controlled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Regeneron's Dupixent (Dupilumab) Achieves 1EP & 2EP in two P-III trial for Inadequately-Controlled Chronic Rhinosinusitis with...

  • October 16, 2018
Pfizer and Astellas Amends Clinical Research Protocols of Xtandi for 2 Phase III to treat Hormone-Sensitive Prostate Cancer (HSPC)

Pfizer and Astellas Amends Clinical Research Protocols of Xtandi for 2 Phase III to treat Hormone-Sensitive Prostate Cancer (HSPC)

  • August 23, 2018
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.